Markets | | | It’s Not Consensus That Matters
Autozone (AZO) made headlines this morning after it reported consensus-beating results for the calendar 1st quarter. While a consensus beat is a great thing, it does not make a stock a buy, especially if the outlook for future growth is in peril. In the case of... Read the Full Story |
|
From Our PartnersREVEALED: $194 Trillion Trump Market Pattern
Trump fires off a tweet and stocks tank…
He gives a speech and the markets soar…
Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets.
And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance. | | | Click here to discover this exciting new trading pattern. |
|
Markets | | |
With restaurant dining rooms only just starting to come back in a lot of places—some have been open for most of a month in at least some capacity—one thing was clear: when the going gets tough, America gets take-out. And take-out pizza was a very big deal in the last month, as reported... Read the Full Story |
|
Markets | | | Shares of the enigmatic athleisure brand Under Armour (NYSE: UAA) (NYSE: UA) have been in a downtrend since peaking in July 2019 at $27.72 on the heels of its last upbeat earnings report. Management ate crow in the following quarters as they missed guidance and continued to lose credibility with shr... Read the Full Story |
|
|
Markets | | |
Technology moves at a mile a minute these days. This is particularly true in the business world, which is rapidly evolving as a result of new and innovative companies that help companies handle their operations in better and more efficient ways. Look no further than some of the fintech companies t... Read the Full Story |
|
Markets | | | Fantasy sports betting platform Draft Kings (NASDAQ: DKNG) shares have accelerated as a pandemic beneficiary play. The absence of live sports events has caused fans to embark upon fantasy sports to meet their fix with the potential to win cash and prizes. Stay-in-shelter isolation mandates generated... Read the Full Story |
|
From Our PartnersBehind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented.
And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots…
What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | | | Claim your FREE copy of Crypto Revolution now. |
|
The Early Bird Stock Of The Day BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. | | View Today's Stock Pick |
|
